Main Article Content
The rapid emergence of antibiotic-resistant bacteria is a threat to global health particularly in the area of healthcare-associate pneumonia (HCAP) where there is high rate of mortality. In general, guidelines should serve as a framework that needs to be complemented by local antibiogram data due to multiple factors influencing the development of multidrug-resistant (MDR) HCAP. Failure to administer prompt and appropriate empirical therapy would often result in a high mortality rate. Based on these concerns, the aim of the study was to evaluate the appropriate empirical use of antibiotic and risk factors of MDR HCAP based on local pathogen resistant pattern. This was a retrospective analysis on HCAP in critical care of a tertiary-care hospital with data from January 2016 to December 2018. Patients diagnosed with HCAP: hospital-associated pneumonia (HAP) and ventilator-associated pneumonia (VAP), with positive bacterial cultures were included into the study. Of the 269 patients and isolates included, 160 (59.5%) had MDR strains. The top causative pathogens isolated were Acinetobacter baumannii (n=104, 38.7%), Pseudomonas aeruginosa (n=66, 24.5%), Klebsiella spp (n==55, 20.4%), and Staphylococcus aureus (n=16, 5.9%). The incidence of inappropriate empirical antibiotic was significantly higher in patients with MDR HCAP (n=135, 84.4%) compared to those with non-MDR HCAP (n=34, 31.2%) (p < 0.001). Mortality was significantly higher in patients receiving inappropriate empirical therapy (n = 118, 72.4%) compared to those receiving appropriate empirical antibiotic (n = 36, 54.5%) (P = 0.009). The independent risk factors for MDR HCAP identified in this study were hypoalbuminemia (odds ratio [OR] 3.43, 95% confidence interval [CI] 1.08 – 10.87, p = 0.036) and indwelling central venous catheter (OR 5.65, 95% CI 1.13 – 28.18, p = 0.035). This work serves as a basis for a center-specific guideline to improve antibiotic use among HCAP patients in intensive care setting.
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3):1700582.
Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409-17.
European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Chikungunya fever. [Internet]. Stockholm: ECDC; 2016.
[cited 22 August 2019]
Available:http://ecdc.europa.eu/en/healthtopics/chikungunya/Pages/Annual epidemiological report2016.aspx
Hoffmann MS, Leibenluft E, Stringaris A, et al. Positive attributes buffer the negative associations between low intelligence and high psychopathology with educational outcomes. J Am Acad Child Adolesc Psychiatry. 2016;55(1):47-53.
Chawla R. Epidemiology, etiology and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control. 2008; 36(4):S93-100.
Herkel T, Uvizl R, Doubravska L, et al. Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(3):448-455.
Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. Accuracy of American Thoracic Society/Infectious diseases society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. Clin Microbiol Infect. 2010;16(7):902-908.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: Clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest. 2005;128(4):2778-2287.
Seligman R, Ramos-Lima LF, Oliveira VD, Sanvicente C, Sartori J, Pacheco EF. Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia. J Bras Pneumol. 2013;39(3):339-348.
Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arc Intern Med. 2008;168(20): 2205–2210. DOI:10.1001/archinte.168.20.2205
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Inf. 2012;18(3): 268-281.
Morata L, Cobos-Trigueros N, Martínez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012;56(9):4833-4837.
Fleiss JL, Levin B, Paik MC. Chapter 18: The measurement of interrater agreement. In: Statistical methods for rates and proportions. 3rd Edition. 2003;598-626.
Haynes RB, Sackett DL, Guyatt GH, Tugwell P. How to do clinical practice research: A new book and a new series in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2006;59(9):873.
Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015;70(3):213-222.
Lat I, Daley MJ, Shewale A, et al. A multicenter, prospective, observational study to determine predictive factors for multidrug‐resistant pneumonia in critically ill adults: The Define Study. Pharmacother: J Human Pharmacol Drug Ther. 2019; 39(3):253-260.
Sadigov A. Risk factors for multidrug-resistant pathogens in hospital-acquired and ventilator-associated pneumonia: Combined therapy is helpful for treatment? Chest. 2018;154(4):179A.
Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
Rosenthal VD, Maki DG, Jamulitrat S, et al. International nosocomial infection control consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control. 2010;38(2):95-104.
Khan RA, Bakry MM, Islahudin F. Appropriate antibiotic administration in critically ill patients with pneumonia. Indian J Pharm Sci. 2015;77(3):299-305.
Zhao JN, Zhang XX, He XC, Yang GR, Zhang XQ, Li HC. The relationship between extensively drug-resistant tuberculosis and multidrug-resistant gram-negative bacilli. PloS One. 2015;10(7): e0134998.
Tosi M, Roat E, De Biasi S, et al. Multidrug resistant bacteria in critically ill patients: A step further antibiotic therapy. J Emerg Crit Care Med. 2018;2:1-9.
Jung JY, Park MS, Kim SE, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis. 2010; 10(1):228.
Guillamet CV, Vazquez R, Noe J, Micek ST, Kollef MH. A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy? Medicine. 2016;95(35).